Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Supernus Pharmaceuticals, Inc. - Common Stock (NQ: SUPN )

31.17 -0.21 (-0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
Supernus Announces First Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Supernus Pharmaceuticals's Earnings: A Preview
Via Benzinga
Supernus to Present at the Bank of America 2023 Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Rejects Supernus Pharma's Minimally Invasive Parkinson's Therapy
Via Benzinga
FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients
Via Benzinga
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Repayment of Convertible Notes
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Present at the Cowen 43rd Annual Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Supernus Enters Into $150 Million Credit Facility
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Present at Two November Healthcare Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Third Quarter 2022 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Provides Regulatory Update on SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Top Medical Specialties Stocks: Trading Opportunities For Next Week - Sunday, Oct. 2
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some medical stock opportunities... 
Via Talk Markets
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Stocks That Made New Highs On Friday, Aug. 19
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs. 
Via Talk Markets
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.